Antigen Map News Today

Adaptive Biotechnologies sports a market-leading advantage with its one-of-a-kind proprietary tech. Read why I rate the ADPT stock a Buy for long-term investors.

Science Writer Adaptive Biotechnologies recently received FDA Emergency Use Authorization (EUA) for T-Detect™ COVID, a test that detects the unique T-cell signature specific to SARS-CoV-2. T-Detect COVID is the first clinical test launched from Adaptive’s TCR-Antigen Map collaboration with Microsoft, highlighting the potential of using T cells in the blood to detect multiple diseases. To learn more about T-Detect, its development and how it compares to antibody testing, Technology Ne...

How The Global Pandemic Is Fueling Increased Revenue Opportunities For Healthcare Stocks - Financialnewsmedia.com News Commentary Share this article Share this article PALM BEACH, Fla., March 17, 2021 /PRNewswire/ -- While many industries have suffered during the global pandemic, there are those few whose fortunes are being made because of COVID. The Personal Protective Equipment Market is one of the latter industries. The mass spread infection scale of COVID-19 has led to a burgeoning demand f...

This T cell-based test is the first indication resulting from Adaptives TCR-Antigen Map collaboration with  Microsoft Corporation (NASDAQ: MSFT). Unlike other tests that detect blood-based antibodies to determine the prior infection with the virus, the T-Detect COVID-19 Test leverages immune repertoire sequencing technology to identify individuals with an adaptive T-cell response to SARS-CoV-2, indicating recent or prior infection. The EUA was issued based on a clinical validation study demo...

06.03.2021 - First and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19 T-Detect COVID correctly confirmed recent or prior COVID-19 infections 97.1% of the time from date ... Seite 1